# Texas Oncology

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/texas-oncology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 65.2 |
| Citations | 661,816 |
| City | Oklahoma City |
| Country | US |
| Description | Texas Oncology is a research organisation in Oklahoma City, US. OpenAlex records 4,962 works and 661,816 citations for it. 1,091 researchers list it as their most recent affiliation. |
| Homepage | http://www.texasoncology.com/ |
| OpenAlex ID | https://openalex.org/I2800124591 |
| Region | Oklahoma |
| Researchers | 1,091 |
| ROR ID | https://ror.org/02ketev28 |
| Type | facility |
| Wikidata ID | https://www.wikidata.org/wiki/Q7707892 |
| Works | 4,962 |

## University papers

Showing 12 of 34.

- [Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer](https://scholariq.org/papers/minimally-invasive-versus-abdominal-radical-hysterectomy-for-cervical-cancer/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma](https://scholariq.org/papers/chronic-stress-promotes-tumor-growth-and-angiogenesis-in-a-mouse-model-of/)
- [Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/rucaparib-in-relapsed-platinum-sensitive-high-grade-ovarian-carcinoma-ariel2/)
- [Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook](https://scholariq.org/papers/bevacizumab-avastin-in-cancer-treatment-a-review-of-15-years-of-clinical/)
- [BAP1 loss defines a new class of renal cell carcinoma](https://scholariq.org/papers/bap1-loss-defines-a-new-class-of-renal-cell-carcinoma/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [RNA interference in the clinic: challenges and future directions](https://scholariq.org/papers/rna-interference-in-the-clinic-challenges-and-future-directions/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/bevacizumab-and-paclitaxel-carboplatin-chemotherapy-and-secondary-cytoreduction/)

## University researchers

- [Robert L. Coleman](https://scholariq.org/researchers/robert-l-coleman/)

## University top topics

Showing 8 of 25.

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.